Fresh Bone Marrow CD34+ Cells, 1 million cells, positively selected
For rapid determination of Nucleofection conditions for primary cell types lacking an Optimized Protocol for the 4D-Nucleofector® X Unit.
For efficient transfection of difficult-to-transfect cell lines, e.g. K-562, Neuro-2A or RAW264.7, in the 4D-Nucleofector® X Unit (100 µL format).
For efficient transfection of difficult-to-transfect cell lines, e.g. K-562, Neuro-2A or RAW264.7, in the 4D-Nucleofector® X Unit (100 µL format).
For efficient transfection of specific primary cells, e.g. HUVEC, in the 4D-Nucleofector® X Unit (20 µL format).
Cryopreserved ampule of Pulmonary Artery Smooth Muscle Cells (PASMC) containing ≥ 500,000 cells
For efficient transfection of specific primary cells, e.g. HUVEC, in the 4D-Nucleofector® X Unit (100 µL format).
For efficient transfection of specific primary cells, e.g. HUVEC, in the 4D-Nucleofector® X Unit (100 µL format).
ProSieve® Color Protein Marker, 10-190 kDa, 100 µL
Discontinuation notification: Based on our product lifecycle management review to maintain high service levels across our portfolios, this product will be discontinued by July 21, 2025
ProSieve® Color Protein Marker, 10-190 kDa, 500 µL
Discontinuation notification: Based on our product lifecycle management review to maintain high service levels across our portfolios, this product will be discontinued by July 21, 2025.
-
References - X-Vivo™Overview of relevant references
-
TechSheet - X-VIVO™ Media SystemsInstructions for how to use the X-VIVO™ Media Series
-
A Novel In Vitro Liver Cell Culture Flow System Allowing Long-Term Metabolism and Hepatotoxicity Studies]Manuscript published in Applied In Vitro Toxicology journal describes improvement of CYP450 phenotype of primary cryopreserved hepatocytes using Quasi Vivo® System
-
TheraPEAK® X-VIVO® Hematopoietic Cell Culture MediumSerum-free, GMP produced medium for cell therapy applications
-
Formulation - Leibovitz Modified Medium (L-15)Composition of L-15 (12-669)
-
Primary Normal Human Cells and MediaIn Vivo Relevance. In Vitro Results. Updated and revised cell content.
-
A Non-Viral Method for Modifying and Expanding Primary T CellsLearn how Lonza’s Cocoon® Platform, 4D-Nucleofector® LV Unit and X-VIVO® 15 Medium are integrated to enable non-viral genetic modification and subsequent expansion of primary T cells in a functionally-closed, automated workflow.
-
Formulation - Leibovitz Medium (L-15)Components present in L-15 (12-700).
-
TechSheet – L-15 Leibovitz MediumHow to use L-15 Medium
-
Building Better In Vitro Models Using the Quasi Vivo® SystemOverview webinar providing details and application data using the Quasi Vivo® Systems delivered by Dr. Kelly Davidge, Scientist at Kirkstall Inc.